Literature DB >> 22589524

Psychomotor performance, subjective and physiological effects and whole blood Δ⁹-tetrahydrocannabinol concentrations in heavy, chronic cannabis smokers following acute smoked cannabis.

David M Schwope1, Wendy M Bosker, Johannes G Ramaekers, David A Gorelick, Marilyn A Huestis.   

Abstract

Δ⁹-Tetrahydrocannabinol (THC) is the illicit drug most frequently observed in accident and driving under the influence of drugs investigations. Whole blood is often the only available specimen collected during such investigations, yet few studies have examined relationships between cannabis effects and whole blood concentrations following cannabis smoking. Nine male and one female heavy, chronic cannabis smokers resided on a closed research unit and smoked ad libitum one 6.8% THC cannabis cigarette. THC, 11-hydroxy-THC and 11-nor-9-carboxy-THC were quantified in whole blood and plasma. Assessments were performed before and up to 6 h after smoking, including subjective [visual analog scales (VAS) and Likert scales], physiological (heart rate, blood pressure and respirations) and psychomotor (critical-tracking and divided-attention tasks) measures. THC significantly increased VAS responses and heart rate, with concentration-effect curves demonstrating counter-clockwise hysteresis. No significant differences were observed for critical-tracking or divided-attention task performance in this cohort of heavy, chronic cannabis smokers. The cannabis influence factor was not suitable for quantifying psychomotor impairment following cannabis consumption and was not precise enough to determine recent cannabis use with accuracy. These data inform our understanding of impairment and subjective effects following acute smoked cannabis and interpretation of whole blood cannabinoid concentrations in forensic investigations.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22589524      PMCID: PMC3523952          DOI: 10.1093/jat/bks044

Source DB:  PubMed          Journal:  J Anal Toxicol        ISSN: 0146-4760            Impact factor:   3.367


  36 in total

1.  Characterization of the absorption phase of marijuana smoking.

Authors:  M A Huestis; A H Sampson; B J Holicky; J E Henningfield; E J Cone
Journal:  Clin Pharmacol Ther       Date:  1992-07       Impact factor: 6.875

2.  Temporal indication of cannabis use by means of THC glucuronide determination.

Authors:  Ute Mareck; Nadine Haenelt; Hans Geyer; Sven Guddat; Matthias Kamber; Rudolf Brenneisen; Mario Thevis; Wilhelm Schänzer
Journal:  Drug Test Anal       Date:  2009-11       Impact factor: 3.345

Review 3.  Methodological issues in pharmacokinetic-pharmacodynamic modelling.

Authors:  E Bellissant; V Sébille; G Paintaud
Journal:  Clin Pharmacokinet       Date:  1998-08       Impact factor: 6.447

4.  Effects of acute smoked marijuana on complex cognitive performance.

Authors:  C L Hart; W van Gorp; M Haney; R W Foltin; M W Fischman
Journal:  Neuropsychopharmacology       Date:  2001-11       Impact factor: 7.853

5.  Pharmacokinetic properties of delta9-tetrahydrocannabinol in serum and oral fluid.

Authors:  Gerold F Kauert; Johannes G Ramaekers; Erhard Schneider; Manfred R Moeller; Stefan W Toennes
Journal:  J Anal Toxicol       Date:  2007-06       Impact factor: 3.367

6.  Delta9-tetrahydrocannabinol (THC), 11-hydroxy-THC, and 11-nor-9-carboxy-THC plasma pharmacokinetics during and after continuous high-dose oral THC.

Authors:  Eugene W Schwilke; David M Schwope; Erin L Karschner; Ross H Lowe; William D Darwin; Deanna L Kelly; Robert S Goodwin; David A Gorelick; Marilyn A Huestis
Journal:  Clin Chem       Date:  2009-10-15       Impact factor: 8.327

7.  Marijuana effect and delta-9-tetrahydrocannabinol plasma level.

Authors:  C W Chiang; G Barnett
Journal:  Clin Pharmacol Ther       Date:  1984-08       Impact factor: 6.875

8.  Cognitive and psychomotor effects in males after smoking a combination of tobacco and cannabis containing up to 69 mg delta-9-tetrahydrocannabinol (THC).

Authors:  Claudine C Hunault; Tjeert T Mensinga; Koen B E Böcker; C Maarten A Schipper; Maaike Kruidenier; Marianne E C Leenders; Irma de Vries; Jan Meulenbelt
Journal:  Psychopharmacology (Berl)       Date:  2008-12-20       Impact factor: 4.530

9.  Alcohol and marijuana: comparative dose effect profiles in humans.

Authors:  S J Heishman; M L Stitzer; G E Bigelow
Journal:  Pharmacol Biochem Behav       Date:  1988-11       Impact factor: 3.533

10.  Reinforcing and subjective effects of oral delta 9-THC and smoked marijuana in humans.

Authors:  L D Chait; J P Zacny
Journal:  Psychopharmacology (Berl)       Date:  1992       Impact factor: 4.530

View more
  31 in total

1.  Evaluation of Breath and Plasma Tetrahydrocannabinol Concentration Trends Postcannabis Exposure in Medical Cannabis Patients.

Authors:  Phillip Olla; Mohd Tazim Ishraque; Stephen Bartol
Journal:  Cannabis Cannabinoid Res       Date:  2020-02-27

2.  Pharmacokinetic Profile of Oral Cannabis in Humans: Blood and Oral Fluid Disposition and Relation to Pharmacodynamic Outcomes.

Authors:  Ryan Vandrey; Evan S Herrmann; John M Mitchell; George E Bigelow; Ronald Flegel; Charles LoDico; Edward J Cone
Journal:  J Anal Toxicol       Date:  2017-03-01       Impact factor: 3.367

Review 3.  Lower-Risk Cannabis Use Guidelines: A Comprehensive Update of Evidence and Recommendations.

Authors:  Benedikt Fischer; Cayley Russell; Pamela Sabioni; Wim van den Brink; Bernard Le Foll; Wayne Hall; Jürgen Rehm; Robin Room
Journal:  Am J Public Health       Date:  2017-06-23       Impact factor: 9.308

4.  Marijuana and the Risk of Fatal Car Crashes: What Can We Learn from FARS and NRS Data?

Authors:  Eduardo Romano; Pedro Torres-Saavedra; Robert B Voas; John H Lacey
Journal:  J Prim Prev       Date:  2017-06

5.  Can oral fluid cannabinoid testing monitor medication compliance and/or cannabis smoking during oral THC and oromucosal Sativex administration?

Authors:  Dayong Lee; Erin L Karschner; Garry Milman; Allan J Barnes; Robert S Goodwin; Marilyn A Huestis
Journal:  Drug Alcohol Depend       Date:  2012-11-10       Impact factor: 4.492

Review 6.  Marijuana Legalization: Impact on Physicians and Public Health.

Authors:  Samuel T Wilkinson; Stephanie Yarnell; Rajiv Radhakrishnan; Samuel A Ball; Deepak Cyril D'Souza
Journal:  Annu Rev Med       Date:  2015-10-19       Impact factor: 13.739

7.  Smoked cannabis' psychomotor and neurocognitive effects in occasional and frequent smokers.

Authors:  Nathalie A Desrosiers; Johannes G Ramaekers; Emeline Chauchard; David A Gorelick; Marilyn A Huestis
Journal:  J Anal Toxicol       Date:  2015-03-04       Impact factor: 3.367

8.  Smoked marijuana attenuates performance and mood disruptions during simulated night shift work.

Authors:  Diana R Keith; Erik W Gunderson; Margaret Haney; Richard W Foltin; Carl L Hart
Journal:  Drug Alcohol Depend       Date:  2017-06-28       Impact factor: 4.492

9.  On the impact of cannabis consumption on traffic safety: a driving simulator study with habitual cannabis consumers.

Authors:  Anne Tank; Tobias Tietz; Thomas Daldrup; Holger Schwender; Florence Hellen; Stefanie Ritz-Timme; Benno Hartung
Journal:  Int J Legal Med       Date:  2019-01-30       Impact factor: 2.686

10.  Controlled vaporized cannabis, with and without alcohol: subjective effects and oral fluid-blood cannabinoid relationships.

Authors:  Rebecca L Hartman; Timothy L Brown; Gary Milavetz; Andrew Spurgin; David A Gorelick; Gary Gaffney; Marilyn A Huestis
Journal:  Drug Test Anal       Date:  2015-08-10       Impact factor: 3.345

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.